Walsh & Hoyt: Prognosis and Treatment

Update Item Information
Identifier wh_ch34_p1610_2
Title Walsh & Hoyt: Prognosis and Treatment
Creator John Kerrison, MD
Affiliation Retina Consultants of Charleston
Subject Neoplasms; Hematologic Neoplasms; Leukemias; Lymphoma; Multiple Myelomas; Plasmacytomas; Histiocytoses; Prognosis; Treatment
Description Without treatment, polycythemia vera is associated with a high incidence of fatal thrombotic or hemorrhagic complications and a median survival of 18 months from the time of first symptoms or signs. Treatment designed to maintain peripheral blood counts and red blood cell mass at normal levels extends median survival to about 10 years. Mortality and morbidity are influenced by treatment modality. In untreated patients and in those treated with phlebotomy alone, thrombotic complications are most common, occurring in 4160% of cases. Acute leukemia occurs in 1.5% of patients with polycythemia vera who are not treated with myelosuppression and in 1013% of patients who are treated. The development of other neoplasms, hemorrhage, and myelofibrosis are other major causes of death. Postpolycythemic myeloid metaplasia, the spent phase of the disease, develops in 1050% of patients.
Date 2005
Language eng
Format application/pdf
Type Text
Source Walsh and Hoyt's Clinical Neuro-Ophthalmology, 6th Edition
Relation is Part of Walsh and Hoyt's Clinical Neuro-Ophthalmology Walsh and Hoyt's Clinical Neuro-Ophthalmology
Collection Neuro-ophthalmology Virtual Education Library: NOVEL http://NOVEL.utah.edu
Publisher Wolters Kluwer Health, Philadelphia
Holding Institution Spencer S. Eccles Health Sciences Library, University of Utah, 10 N 1900 E SLC, UT 84112-5890
Rights Management Copyright 2005. For further information regarding the rights to this collection, please visit: https://NOVEL.utah.edu/about/copyright
ARK ark:/87278/s6wq3c83
Setname ehsl_novel_whts
ID 185729
Reference URL https://collections.lib.utah.edu/ark:/87278/s6wq3c83
Back to Search Results